Literature DB >> 30292644

Organotypic slice cultures of pancreatic ductal adenocarcinoma preserve the tumor microenvironment and provide a platform for drug response.

Chae Yoon Lim1, Jae Hyuck Chang2, Won Sun Lee3, Kang Min Lee1, Young Chul Yoon4, Jeana Kim5, Il Young Park4.   

Abstract

BACKGROUND: /Objective: The conventional models currently used to evaluate various anti-tumor therapeutic agents are not sufficient for representing human pancreatic ductal adenocarcinoma (PDA), which has a unique tumor microenvironment. We aimed to produce an organotypic slice culture model from human PDA that resembles the in vivo situation and to evaluate the responses of PDA slices to established cytotoxic drugs.
METHODS: PDA tissues were obtained from 10 patients who underwent pancreatic resection. The tissues were sliced by a vibratome, and the tumor slices were then cultured. The viability of tumor slices during slice culture was evaluated using H&E and immunohistochemical staining, and stromal cells were demonstrated. The effects of cytotoxic drugs on PDA cell lines and slices were analyzed.
RESULTS: Tumor slices maintained their surface areas and tissue viability for at least five days during culture. Preserved proliferation and apoptosis in tumor slices were observed by the expression of Ki-67 and cleaved caspase-3. Stromal cells including macrophages (CD68+ and CD163+), T cells (CD3+, CD8+, and FOXP3+), and myeloid cells (CD11b+) were present throughout the culture period. Staurosporine, gemcitabine, and cisplatin treatment of PDA cell lines and tumor slices exerted proportional cytotoxic effects in terms of MTT viability, tumor cell number, and Ki-67 and cleaved caspase-3 expression.
CONCLUSIONS: Organotypic human PDA slice cultures preserved their viability and tumor microenvironment for at least five days during slice culture. PDA slice culture appears to be a feasible preclinical test model to assess the response to anti-tumor agents.
Copyright © 2018 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Immune cells; Microenvironment; Pancreatic cancer; Slice culture

Mesh:

Substances:

Year:  2018        PMID: 30292644     DOI: 10.1016/j.pan.2018.09.009

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  14 in total

1.  3D Tumor Spheroid Models for In Vitro Therapeutic Screening of Nanoparticles.

Authors:  Simonas Daunys; Agnė Janonienė; Indrė Januškevičienė; Miglė Paškevičiūtė; Vilma Petrikaitė
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Addressing Patient Specificity in the Engineering of Tumor Models.

Authors:  Laura J Bray; Dietmar W Hutmacher; Nathalie Bock
Journal:  Front Bioeng Biotechnol       Date:  2019-09-12

3.  Calcium channel blockers potentiate gemcitabine chemotherapy  in pancreatic cancer.

Authors:  Daniel R Principe; Alexandre F Aissa; Sandeep Kumar; Thao N D Pham; Patrick W Underwood; Rakesh Nair; Rong Ke; Basabi Rana; Jose G Trevino; Hidayatullah G Munshi; Elizaveta V Benevolenskaya; Ajay Rana
Journal:  Proc Natl Acad Sci U S A       Date:  2022-04-27       Impact factor: 12.779

4.  An Ex Vivo Brain Slice Model to Study and Target Breast Cancer Brain Metastatic Tumor Growth.

Authors:  Lorela Ciraku; Rebecca A Moeller; Emily M Esquea; Wiktoria A Gocal; Edward J Hartsough; Nicole L Simone; Joshua G Jackson; Mauricio J Reginato
Journal:  J Vis Exp       Date:  2021-09-22       Impact factor: 1.424

Review 5.  Patient-derived tumour models for personalized therapeutics in urological cancers.

Authors:  Arjanneke F van de Merbel; Geertje van der Horst; Gabri van der Pluijm
Journal:  Nat Rev Urol       Date:  2020-11-10       Impact factor: 14.432

Review 6.  Temporal single-cell regeneration studies: the greatest thing since sliced pancreas?

Authors:  Juan Domínguez-Bendala; Mirza Muhammad Fahd Qadir; Ricardo Luis Pastori
Journal:  Trends Endocrinol Metab       Date:  2021-05-15       Impact factor: 10.586

7.  CD40 Agonists Alter the Pancreatic Cancer Microenvironment by Shifting the Macrophage Phenotype toward M1 and Suppress Human Pancreatic Cancer in Organotypic Slice Cultures.

Authors:  Chae Yoon Lim; Jae Hyuck Chang; Won Sun Lee; Jeana Kim; Il Young Park
Journal:  Gut Liver       Date:  2021-12-21       Impact factor: 4.321

8.  PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma.

Authors:  Marlon Hußtegge; Ngoc Anh Hoang; Jakob Rebstock; Astrid Monecke; Ines Gockel; Arved Weimann; Guido Schumacher; Ingo Bechmann; Florian Lordick; Sonja Kallendrusch; Justus Körfer
Journal:  Oncoimmunology       Date:  2021-08-18       Impact factor: 8.110

Review 9.  Patient-Derived Explants as a Precision Medicine Patient-Proximal Testing Platform Informing Cancer Management.

Authors:  Abby R Templeton; Penny L Jeffery; Patrick B Thomas; Mahasha P J Perera; Gary Ng; Alivia R Calabrese; Clarissa Nicholls; Nathan J Mackenzie; Jack Wood; Laura J Bray; Ian Vela; Erik W Thompson; Elizabeth D Williams
Journal:  Front Oncol       Date:  2021-12-20       Impact factor: 6.244

10.  Quantification of fluorophore distribution and therapeutic response in matched in vivo and ex vivo pancreatic cancer model systems.

Authors:  Allison Solanki; Diana King; Guillaume Thibault; Lei Wang; Summer L Gibbs
Journal:  PLoS One       Date:  2020-02-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.